Oxygen-wasting effect of inotropy: Is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan

Circulation: Heart Failure

Volumn 3, Issue 2, 2010, Pages 277-285

  Müller, Stig ^a,b   How, Ole Jakob ^a,b   Jakobsen, Øyvind ^a,b   Hermansen, Stig Eggen ^a,b   Røsner, Assami ^a,b   Stenberg, Thor Allan ^a,b   Myrmel, Truls ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Contractility; Inotropic agents; Metabolism; Myocardial; Oxygen; Stunning

Indexed keywords

DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANIMAL EXPERIMENT; ARTICLE; ASYMPTOTIC PRESSURE DECAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; END SYSTOLIC ELASTANCE; EXPERIMENTAL PIG; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; INOTROPIC OXYGEN WASTING; INOTROPISM; LEFT CORONARY ARTERY; LEFT VENTRICULAR CORONARY BLOOD FLOW; LOADING DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MEAN PULMONARY ARTERIAL PRESSURE; NONHUMAN; PRELOAD RECRUITABLE STROKE WORK; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; STROKE WORK; STUNNED HEART MUSCLE; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA; VASODILATATION; ANALYSIS OF VARIANCE; ANIMAL; DISEASE MODEL; DRUG EFFECT; HEART CONTRACTION; OXYGEN CONSUMPTION; SWINE;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOBUTAMINE; HYDRAZONES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL STUNNING; OXYGEN CONSUMPTION; PYRIDAZINES; SWINE;

EID: 77951924855     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.865519     Document Type: Article

References (30)

1. Klocke FJ, Kaiser GA, Ross J Jr, Braunwald E. Mechanism of increase of myocardial oxygen uptake produced by catecholamines. Am J Physiol. 1965;209:913-918.
2. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247-277.
3. 2 consumption and contractility to catecholamines in dogs. Am J Physiol. 1991;261: H196-H205.
4. Myrmel T, Korvald C. New aspects of myocardial oxygen consumption. Scand Cardiovasc J. 2000;34:233-241.
5. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305-315.
6. Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail. 2004;6:673-676.
7. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic J, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
8. 2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg. 2008;34:326-331.
9. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-1509.
10. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, Warltier DC. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol. 1997;29:563-573.
11. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996;279:120-127.
12. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997;61:596-607.
13. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27:1908-1920.
14. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res. 1982;50:273-286.
15. Elbeery JR, Lucke JC, Feneley MP, Maier GW, Owen CH, Lilly RE, Savitt MA, Mickey MS, Gall SA Jr, Davis JW, Vantright P, Rankin JS, Glower DD. Mechanical determinants of myocardial oxygen consumption in conscious dogs. Am J Physiol. 1995;269: H609-H620.
16. Nozawa T, Cheng CP, Noda T, Little WC. Relation between left ventricular oxygen consumption and pressure-volume area in conscious dogs. Circulation. 1994;89:810-817.
17. Prabhu SD, Freeman GL. Left ventricular energetics in closed-chest dogs. Am J Physiol. 1993;265: H1048-H1055.
18. Korvald C, Elvenes OP, Aghajani E, Myhre ES, Myrmel T. Postischemic mechanoenergetic inefficiency is related to contractile dysfunction and not altered metabolism. Am J Physiol. 2001;281: H2645-H2653.
19. Sarnoff SJ, Braunwald E, Welch GH Jr, Case RB, Stainsby WN, Macruz R. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol. 1958;192:148-156.
20. Nordhaug D, Steensrud T, Korvald C, Aghajani E, Myrmel T. Preserved myocardial energetics in acute ischemic left ventricular failure-studies in an experimental pig model. Eur J Cardiothorac Surg. 2002;22:135-142.
21. Walker AA, Janicki JS, Weber KT, Russell RO Jr, Rackley CE. Equations for the calculation of mean ejection pressure. Cardiovasc Res. 1973;7:567-571.
22. Korvald C, Elvenes OP, Ytrebo LM, Sorlie DG, Myrmel T. Oxygenwasting effect of inotropy in the 'virtual work model.' Am J Physiol. 1999;276: H1339-H1345.
23. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol. 2005;289: H501-H512.
24. Kusuoka H, Hoffman JI. Advice on statistical analysis for Circulation Research. Circ Res. 2002;91:662-671.
25. Rossinen J, Harjola VP, Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute Card Care. 2008;10:209-213.
26. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-110.
27. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkart L, Padley RJ, Pöder P. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. J Am Med Assoc. 2007;297:1883-1891.
28. Path GJ, Dai XZ, Schwartz JS, Benditt DG, Bache RJ. Effect of amiodarone with and without polysorbate 80 on myocardial oxygen consumption and coronary blood flow during treadmill exercise in the dog. J Cardiovasc Pharmacol. 1991;18:11-16.
29. Earl GL, Fitzpatrick JT. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Ann Pharmacother. 2005;39:1888-1896.
30. Hoerter J, Gonzales-Barroso M, Couplan E, Mateo P, Gelly C, Cassard-Doulcier AM, Diolez P, Buillard F. Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemicreperfusion damage. Circulation. 2004;110:528-533.